By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Aiming for better targeting and better delivery of treatments for GI and other autoimmune diseases.
The novel mechanism of action (MoA) of Landos Biopharma’s lead candidate is stimulating Lanthionine Synthetase C-Like 2 (LANCL2), a therapeutic target that can play a role in numerous autoimmune conditions. Unlike current treatments that target a single cytokine, the Landos compounds suppress multiple inflammatory proteins such as TNF-alpha, interferon gamma (IFNγ), and monocyte chemoattractant protein- 1 (MCP-1) rather than only a single one, while boosting the body’s own anti-inflammatory response. Lead candidate BT-11, an orally active, gut-targeting small molecule therapeutic, is heading into Phase 1 development in mid- 2018 for treating both clinical manifestations of inflammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC).